{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:11:55Z","timestamp":1775002315836,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106704","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T14:25:03Z","timestamp":1756045503000},"page":"106704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Severe infections in pediatric MS and related disorders patients on B-cell depleting therapies compared to sphingosine-1-receptor modulators"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-7368","authenticated-orcid":false,"given":"Sarah","family":"Conway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106704_bib0001","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","article-title":"Pediatric multiple sclerosis: a review","volume":"18","author":"Alroughani","year":"2018","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103359","article-title":"COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis","volume":"57","author":"Barzegar","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106704_bib0005","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1007\/s10072-022-06287-2","article-title":"Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies","volume":"43","author":"Bellinvia","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106704_bib0006","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10072-020-04434-1","article-title":"Experience with rituximab therapy in a real-life sample of multiple sclerosis patients","volume":"41","author":"Bellinvia","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106704_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16228","article-title":"Rituximab treatment in pediatric-onset multiple sclerosis","volume":"31","author":"Breu","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0008","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of Fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106704_bib0009","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/1352458520936934","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: results from the PARADIGMS study","volume":"27","author":"Chitnis","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106704_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105849","article-title":"Anti-CD20 therapies for pediatric-onset multiple sclerosis: a systematic review","volume":"91","author":"Etemadifar","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106704_bib0011","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106704_bib0012","article-title":"Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study","volume":"15","author":"Fernandes","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0013","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of Rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106704_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.27026","article-title":"Hospital-treated infections and risk of disability worsening in multiple sclerosis","volume":"96","author":"Hu","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106704_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple sclerosis, disease-modifying therapies, and infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106704_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","article-title":"Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments","volume":"145","author":"Malani Shukla","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106704_bib0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106704_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10067-023-06809-z","article-title":"Nationwide analysis of neuromyelitis optica in systemic lupus erythematosus and Sjogren's syndrome","volume":"43","author":"Sami","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2025.106704_bib0022","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/13524585231151948","article-title":"Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2","volume":"29","author":"Schreiner","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106704_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106191","article-title":"Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study","volume":"93","author":"Smolik","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106704_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106704_bib0025","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/jnnp-2023-333206","article-title":"Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study","volume":"95","author":"Virtanen","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:42Z","timestamp":1774998942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"alternative-id":["S2211034825004468"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106704","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe infections in pediatric MS and related disorders patients on B-cell depleting therapies compared to sphingosine-1-receptor modulators","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106704"}}